by 
The HIV diagnostics test market comprises tests that are used for the detection of Human Immunodeficiency Virus (HIV) antibodies and antigens in the blood. HIV diagnostics tests offer advantages such as early detection of HIV infection, assessment of HIV disease progression, and detection of HIV antibodies in blood donors and pregnant women. The rising incidence of HIV/AIDS globally and increased availability of rapid testing services are driving the demand for HIV diagnostic tests.
The Global HIV Diagnostics Market size is estimated to be valued at US$ 4,263.62 mn in 2024 and is expected to exhibit a CAGR of 9.0% over the forecast period of 2023 to 2030. HIV diagnostics tests have played a critical role by facilitating effective treatment and management of HIV infections. Early detection through diagnostic testing has increased life expectancy of HIV positive patients by controlling the infection at its early stages.
Key Takeaways
Key players operating in the HIV Diagnostics market are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
The growing prevalence of HIV infections globally is a major factor driving the demand for HIV diagnostic tests. As per WHO estimates, around 38 million people were living with HIV globally in 2020. Widespread awareness initiatives undertaken by governments and NGOs are encouraging more people to opt for diagnostic testing.
The market is witnessing an increasing shift towards point-of-care testing owing to advantages such as immediate results, affordable price-points and ease of use. Rapid HIV tests can be performed without specialized equipment or laboratories and have enhanced accessibility to testing services in remote locations.
Market Key Trends
The increasing adoption of fourth generation HIV diagnostic tests is a key trend in the market. Fourth generation assays offer improved sensitivity and are capable of detecting both HIV antibodies and antigens, facilitating early diagnosis even during the initial stage of infection. These tests reduce the window period allowing for detection within 16-34 days after infection as against 25-45 days with third generation tests. Introduction of self-testing technologies is also transforming the HIV testing landscape to reach more individuals.
Porter’s Analysis
Threat of new entrants: New companies entering into the HIV diagnostics test market will find it difficult to acquire the required technology, expertise and distribution networks possessed by established players.
Bargaining power of buyers: Due to presence of large patient pool, buyers have moderate bargaining power in this market.
Bargaining power of suppliers: Established diagnostic test kit manufacturers have significant influence over suppliers of raw materials and components.
Threat of new substitutes: There exists low threat from alternative diagnostic tests due to lack of substitutes for HIV testing.
Competitive rivalry: Intense competition exists between major diagnostic companies to gain more market share.
Geographical Regions
North America currently dominates the global HIV diagnostics test market in terms of value due to rising prevalence of HIV/AIDS cases and availability of advanced diagnostics. According to CDC, approximately 1.1 million people are living with HIV in the US.
The Asia Pacific region is poised to witness the fastest growth during the forecast period. This can be attributed to increasing initiatives by public-private organizations to spread awareness about HIV testing in developing countries and growing healthcare expenditure. Countries like China and India have emerged as new hotspots for HIV infections, thereby propelling demand.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
